Literature DB >> 22891374

Cohort reporting improves hypertension care for refugees.

James Mullins.   

Abstract

Entities:  

Mesh：

Year:  2012        PMID： 22891374     DOI： 10.1016/s0140-6736(12)61315-4

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  5 in total

1.  Noncommunicable diseases among HIV-infected persons in low-income and middle-income countries: a systematic review and meta-analysis.

Authors:  Pragna Patel; Charles E Rose; Pamela Y Collins; Bernardo Nuche-Berenguer; Vikrant V Sahasrabuddhe; Emmanuel Peprah; Susan Vorkoper; Sonak D Pastakia; Dianne Rausch; Naomi S Levitt
Journal:  AIDS       Date:  2018-07-01       Impact factor: 4.177

2.  San Antonio refugees: Their demographics, healthcare profiles, and how to better serve them.

Authors:  Fadi W Adel; Eden Bernstein; Michael Tcheyan; Shane Ali; Heidi Worabo; Moshtagh Farokhi; Andrew E Muck
Journal:  PLoS One       Date:  2019-02-19       Impact factor: 3.240

3.  Improved Blood Pressure Control to Reduce Cardiovascular Disease Morbidity and Mortality: The Standardized Hypertension Treatment and Prevention Project.

Authors:  Pragna Patel; Pedro Ordunez; Donald DiPette; Maria Cristina Escobar; Trevor Hassell; Fernando Wyss; Anselm Hennis; Samira Asma; Sonia Angell
Journal:  J Clin Hypertens (Greenwich)       Date:  2016-07-04       Impact factor: 3.738

4.  Adapting HIV patient and program monitoring tools for chronic non-communicable diseases in Ethiopia.

Authors:  Mekitew Letebo; Fassil Shiferaw
Journal:  Global Health       Date:  2016-06-02       Impact factor: 4.185

5.  Blood pressure measurements with the OptiBP smartphone app validated against reference auscultatory measurements.

Authors:  Patrick Schoettker; Jean Degott; Gregory Hofmann; Martin Proença; Guillaume Bonnier; Alia Lemkaddem; Mathieu Lemay; Raoul Schorer; Urvan Christen; Jean-François Knebel; Arlene Wuerzner; Michel Burnier; Gregoire Wuerzner
Journal:  Sci Rep       Date:  2020-10-20       Impact factor: 4.379
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.